# A Tolerability and Pharmacokinetics Study of SHR6390 in Advanced Melanoma Patients

> **NCT02671513** · PHASE1 · UNKNOWN · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 30 (estimated)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** SHR6390

## Key facts

- **NCT ID:** NCT02671513
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-01
- **Primary completion:** 2016-11
- **Final completion:** 2017-04
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2016-04-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02671513

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02671513, "A Tolerability and Pharmacokinetics Study of SHR6390 in Advanced Melanoma Patients". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT02671513. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*